BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1213 related articles for article (PubMed ID: 27708225)

  • 1. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
    Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.
    Huang JM; Zhang GN; Shi Y; Zha X; Zhu Y; Wang MM; Lin Q; Wang W; Lu HY; Ma SQ; Cheng J; Deng BF
    Sci Rep; 2014 Jan; 4():3840. PubMed ID: 24452475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
    Craveiro V; Yang-Hartwich Y; Holmberg JC; Joo WD; Sumi NJ; Pizzonia J; Griffin B; Gill SK; Silasi DA; Azodi M; Rutherford T; Alvero AB; Mor G
    Cancer Med; 2013 Dec; 2(6):751-62. PubMed ID: 24403249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.
    Li Z; Block MS; Vierkant RA; Fogarty ZC; Winham SJ; Visscher DW; Kalli KR; Wang C; Goode EL
    Tumour Biol; 2016 Oct; 37(10):13279-13286. PubMed ID: 27460076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
    d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
    PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
    Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X
    BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
    Dutta S; Wang FQ; Wu HS; Mukherjee TJ; Fishman DA
    Gynecol Oncol; 2011 Oct; 123(1):129-37. PubMed ID: 21782227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.
    Lu H; Liu Y; Wang D; Wang L; Zhou H; Xu G; Xie L; Wu M; Lin Z; Yu Y; Li G
    Tumour Biol; 2016 Aug; 37(8):11469-77. PubMed ID: 27012551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
    Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase-10 regulates stemness of ovarian cancer stem-like cells by activation of canonical Wnt signaling and can be a target of chemotherapy-resistant ovarian cancer.
    Mariya T; Hirohashi Y; Torigoe T; Tabuchi Y; Asano T; Saijo H; Kuroda T; Yasuda K; Mizuuchi M; Saito T; Sato N
    Oncotarget; 2016 May; 7(18):26806-22. PubMed ID: 27072580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.
    Wen KC; Sung PL; Hsieh SL; Chou YT; Lee OK; Wu CW; Wang PH
    Oncotarget; 2017 Apr; 8(17):29013-29027. PubMed ID: 28423672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
    Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
    Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals.
    Chen SS; Michael A; Butler-Manuel SA
    Discov Med; 2012 Jan; 13(68):7-17. PubMed ID: 22284780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2.
    Xia B; Lin M; Dong W; Chen H; Li B; Zhang X; Hou Y; Lou G
    J Biochem Mol Toxicol; 2018 Aug; 32(8):e22168. PubMed ID: 30004169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSMB4 expression associates with epithelial ovarian cancer growth and poor prognosis.
    Liu R; Lu S; Deng Y; Yang S; He S; Cai J; Qiang F; Chen C; Zhang W; Zhao S; Qian L; Mao G; Wang Y
    Arch Gynecol Obstet; 2016 Jun; 293(6):1297-307. PubMed ID: 26439929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.